SCHEMBL4243787

SCHEMBL4243787

COCCCNC(=O)c1cc2c(nc(C)n2C)c2c1CCC1(Cc3ccccc3C1)N2

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 2/20 0.38
KMT2A Q03164 4/20 0.36
HSD17B10 Q99714 5/20 0.36
KDM4E B2RXH2 5/20 0.36
ALDH1A1 P00352 3/20 0.36
HPGD P15428 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
LMNA P02545 3/20 0.35
TP53 P04637 2/20 0.35
MAPK1 P28482 1/20 0.35
THRB P10828 1/20 0.35
MAPT P10636 2/20 0.35
MEN1 O00255 2/20 0.35
PKM P14618 1/20 0.35
HTT P42858 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
NAMPT P43490 1/20 0.35
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4242410 0.95 ALDH1A1 (0.36) KMT2AHSD17B10KDM4EALDH1A1HPGD
Hydrochloric Acid SCHEMBL4245930 0.94 ALDH1A1 (0.35) TRPA1KMT2AHSD17B10KDM4EALDH1A1
Malonic Acid SCHEMBL4246390 0.92 ALDH1A1 (0.34) KMT2AHSD17B10KDM4EALDH1A1HPGD
SCHEMBL4241781 0.92 OPRL1 (0.34) HSD17B10KDM4EALDH1A1HPGDMAPT
Fumaric Acid SCHEMBL4244556 0.91 KMT2A (0.33) KMT2AHSD17B10KDM4EALDH1A1HPGD
Maleic Acid SCHEMBL4244553 0.91 KMT2A (0.33) KMT2AHSD17B10KDM4EALDH1A1HPGD
SCHEMBL4239937 0.90 CDK2 (0.34) KMT2AHSD17B10KDM4EALDH1A1HPGD
SCHEMBL4235958 0.88 CHIA (0.32) HSD17B10KDM4ESMN1; SMN2NPSR1
SCHEMBL4241846 0.87 HCN1 (0.30)
SCHEMBL4240859 0.85 CRBN (0.32) KDM4EALDH1A1SMN1; SMN2LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090093473-A1 Spiro-benzimidazoles as inhibitors of gastric acid secretion NYCOMED GMBH (DE) 2009-04-09 US claimed
EP-1899338-A1 SPIRO-BENZIMIDAZOLES AS INHIBITORS OF GASTRIC ACID SECRETION Nycomed GmbH (DE) 2008-03-19 EP claimed
WO-2006134111-A1 SPIRO-BENZIMIDAZOLES AS INHIBITORS OF GASTRIC ACID SECRETION NYCOMED GMBH (DE) 2006-12-21 WO claimed
US-20090093473-A1 Spiro-benzimidazoles as inhibitors of gastric acid secretion NYCOMED GMBH (DE) 2009-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093473-A1 Spiro-benzimidazoles as inhibitors of gastric acid secretion GIPR, PGC, SLC10A2 TRPA1 537/4885KMT2A 4175/4885HSD17B10 664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.